India, May 6 -- Apimeds Pharmaceuticals US, Inc. (APUS) yesterday said it has reached a comprehensive settlement with Inscobee, removing all outstanding disputes tied to its December 2025 merger with MindWave Innovations and allowing the long-delayed transaction and $100 million PIPE financing to move forward.
The settlement resolves governance challenges that had stalled progress for months, including disagreements over voting rights and board control. With the agreement now in place, Apimeds expects its common stock to resume trading on the NYSE American on Tuesday, May 5, pending exchange approval.
Under the terms of the settlement, the Inscobee parties confirmed that prior attempts to remove Apimeds' directors were invalid and that ex...